Hamburg Warns Some Of Congress’ ‘Cures’ May Be ‘Dangerous’
This article was originally published in The Pink Sheet Daily
Executive Summary
Outgoing FDA Commissioner also cautions against unfunded mandates in Energy & Commerce’s biomedical reform proposal.
You may also be interested in...
AdvaMed Innovation Agenda Aligns With Capitol Hill Objectives
A review of the medical device trade group's “Innovation Agenda” for the coming year and the recent 21st Century Cures proposal in Congress suggests a supportive environment for the association's priorities.
FDA Lands Duke’s Califf As Top Deputy, Potential Next Commissioner
Renowned cardiologist and clinical trialist Robert Califf will join FDA in February as deputy commissioner for medical products and tobacco.
FDA’s Authority Looks Safe From Judicial Interference Following Supreme Court Abortion Pill Arguments
The agency's and the pharma industry’s worst fears – that a potential ruling in the mifepristone case might usurp the FDA’s scientific authority and throw the stability of the US drug approval process into question – seem unlikely to materialize as the majority of the Supreme Court justices signal the Alliance for Hippocratic Medicine lacks standing to sue.